Burn

Summary

Burn (MONDO:0043519) is a disease and 503 clinical trials. Top therapeutic interventions include propranolol, mafenide, and neostigmine. A subtype of injury — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 503

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	burn
Mondo ID	MONDO:0043519
MeSH	D002056
ICD-10-CM	T20-T25
NCIT	C34441
SNOMED CT	125666000
Is cancer (heuristic)	no

Also known as: Burn · burn · Burn(s)

Disease family

This is a subtype of injury. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: injury › burn

Related subtypes (9): ischemia reperfusion injury, bone fracture, acute lung injury, spinal injury, radiation injury, ankle injury, nervous system injury, frostbite, head injury

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

8 approved, 10 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Alcohol	Approved (phase 4)
Bacitracin	Approved (phase 4)
Benzocaine	Approved (phase 4)
Isopropyl Alcohol	Approved (phase 4)
Lidocaine	Approved (phase 4)
Menthol	Approved (phase 4)
Povidone-Iodine	Approved (phase 4)
Zinc Oxide	Approved (phase 4)
Ergocalciferol	Phase 3 (in late-stage trials)
Ibuprofen	Phase 3 (in late-stage trials)
Neostigmine	Phase 3 (in late-stage trials)
Nitrogen	Phase 3 (in late-stage trials)
Nitrous Oxide	Phase 3 (in late-stage trials)
Oxygen	Phase 3 (in late-stage trials)
Petrolatum	Phase 3 (in late-stage trials)
Stem Bromelain	Phase 3 (in late-stage trials)
Sugammadex	Phase 3 (in late-stage trials)
Tranexamic Acid	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Albumin Human, Dexmedetomidine, Fenofibrate, Heparin, Insulin Human, Itraconazole, Ketoconazole, Melatonin, Metformin, Nefopam, Nystatin, Oxandrolone, Pirfenidone, Propranolol, Ramelteon, Rosuvastatin, Silver, Silver Nitrate, Sodium Chloride, Somatropin, Sulfadiazine, Tetracycline, Thrombin, Vitamin E.

Clinical trials & evidence

Clinical trials

Clinical trials: 503.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	356
PHASE2	34
PHASE4	30
PHASE3	25
PHASE2/PHASE3	20
PHASE1	17
PHASE1/PHASE2	15
EARLY_PHASE1	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04589442	PHASE4	RECRUITING	Microsurfaced Grafts in Deep Burn Wounds
NCT05217160	PHASE4	RECRUITING	Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers
NCT06379724	PHASE4	RECRUITING	Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft
NCT06506565	PHASE4	RECRUITING	Low-Dose Ketamine Infusion During Burn Wound Care
NCT00149123	PHASE4	COMPLETED	Low-dose Hydrocortisone in Acutely Burned Patients
NCT00156988	PHASE4	COMPLETED	The Effect of Two Versus Ten Days Application of Flammacerium in Partial Thickness Burns
NCT00297752	PHASE4	COMPLETED	Treatment of Facial Burns With Flammacerium Compared to Flammazine and the Impact of Facial Burns on Psychosocial Wellbeing
NCT00326859	PHASE4	TERMINATED	Comparison of Monitored Anesthesia Care Using Remifentanil or Fentanyl for Major Dressing Changes in Burns
NCT00634166	PHASE4	TERMINATED	Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group
NCT00860379	PHASE4	TERMINATED	The Effect of Selenium Supplementation Among Pediatric Patients With Burns
NCT01012648	PHASE4	UNKNOWN	Early Fluid Resuscitation With Balanced HES 130/0.4 [6%] in Severe Burn Injury
NCT01668030	PHASE4	COMPLETED	Comparison of Wound Bed Establishment in Facial Burns
NCT01689506	PHASE4	TERMINATED	Fluid Resuscitation in Patients Suffering From Burns Injury
NCT01926392	PHASE4	COMPLETED	Comparison of a Water-soluble Topical Antimicrobial to Silver Sulfadiazine in Partial Thickness Burns
NCT02813213	PHASE4	UNKNOWN	Effectiveness Comparison of Skin Micro-grafts vs Meshed Split Thickness Skin Grafts
NCT02952378	PHASE4	COMPLETED	Volume Kinetics for Hyperoncotic Albumin in Burn Patients as Well as for Healthy Subjects
NCT03002506	PHASE4	TERMINATED	Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns
NCT03049930	PHASE4	UNKNOWN	Intraoperative Low-dose Ketamine Infusion as the Main Analgesic in Burn Patients
NCT03113253	PHASE4	COMPLETED	TRANexamic Acid to Reduce Bleeding in BURN Surgery
NCT03854344	PHASE4	COMPLETED	Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
NCT03941535	PHASE4	UNKNOWN	Comparison of Vitamin K Doses in Patients With Larger Burn Injuries
NCT04152096	PHASE4	COMPLETED	Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Burns
NCT04162639	PHASE4	WITHDRAWN	The Relationship Between Cadaveric Allograft Skin and HLA-Sensitivity in Burn Patients
NCT04516148	PHASE4	COMPLETED	A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting
NCT04681638	PHASE4	TERMINATED	Plasma Resuscitation Without Lung Injury
NCT04682782	PHASE4	UNKNOWN	Intraoperative Small-dose Esketamine Infusion for Pain Control in Burn Patients
NCT04781348	PHASE4	COMPLETED	Efficacy of Platelet Rich Plasma Injection Plus Fat Grafting as Compared to Fat Grafting Alone on Burn Scar by Using Vancouver Scar Scale
NCT05084248	PHASE4	COMPLETED	Vitamin D Deficiency in Adults Following a Major Burn Injury
NCT05465226	PHASE4	COMPLETED	Oliceridine in Patients With Acute Burn Injuries
NCT06142591	PHASE4	COMPLETED	Oxycodone (10, 20 mg) in a Postoperative Dressing
NCT06223269	PHASE3	RECRUITING	Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting
NCT06745557	PHASE3	RECRUITING	Phase III Study with an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents
NCT00243243	PHASE3	COMPLETED	Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn
NCT00261690	PHASE2/PHASE3	COMPLETED	Virtual Reality Pain Control During Burn Wound Care
NCT00324311	PHASE3	COMPLETED	Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care
NCT00426972	PHASE3	COMPLETED	Trial of Zesteem (Estradiol) in Healing of Split Thickness Skin Graft Donor Sites
NCT00539097	PHASE2/PHASE3	TERMINATED	Evaluation Perioperative Nutrition on Donor Site Healing in Patients Undergoing Reconstructive Burn Surg
NCT00548314	PHASE3	COMPLETED	Dermal Substitute and Topical Negative Pressure in Burns
NCT00591162	PHASE2/PHASE3	TERMINATED	Bone Disease in Severely Burned Children
NCT00591604	PHASE3	WITHDRAWN	High-Dose Vitamin D Deficiency in Burn Injury

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PROPRANOLOL	4	15
MAFENIDE	4	4
NEOSTIGMINE	4	4
SULFADIAZINE, SILVER	4	4
BACITRACIN	4	3
CLINDAMYCIN	4	3
FENOFIBRATE	4	3
GLYCOPYRRONIUM	4	3
OXANDROLONE	4	2
SOMATROPIN	4	2
ALBUMIN HUMAN	4	1
BUPIVACAINE HYDROCHLORIDE	4	1
CEFAZOLIN	4	1
CEFTOLOZANE	4	1
CETIRIZINE	4	1
CHYMOTRYPSIN	4	1
CIPROFLOXACIN	4	1
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	4	1
DALFAMPRIDINE	4	1
ERGOCALCIFEROL	4	1
ESKETAMINE	4	1
ESTRADIOL	4	1
GENTAMICIN	4	1
GLUTAMINE	4	1
HEPARIN	4	1
HYDROCORTISONE	4	1
HYDROXYETHYL STARCH 130/0.4	4	1
INDOCYANINE GREEN	4	1
INDOCYANINE GREEN ACID FORM	4	1
ITRACONAZOLE	4	1